Legislation allowing the US FDA to take into consideration a prescription drug's abuse or misuse potential when considering approval or withdrawal from the market should be limited to controlled substances, Commissioner Scott Gottlieb told a House Energy & Commerce Health Subcommittee hearing March 21.
The hearing was the second of a planned three hearings by the Energy & Commerce Committee on public health solutions...







